Veracyte (VCYT) Scheduled to Post Earnings on Tuesday

Veracyte (NASDAQ:VCYT) is scheduled to be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Veracyte to post earnings of ($0.19) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Veracyte (NASDAQ:VCYT) last released its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03. Veracyte had a negative net margin of 20.61% and a negative return on equity of 2.02%. The business had revenue of $98.20 million for the quarter, compared to analysts’ expectations of $95.49 million. On average, analysts expect Veracyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Veracyte Stock Performance

Shares of VCYT stock opened at $20.35 on Friday. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -19.76 and a beta of 1.65. Veracyte has a one year low of $18.61 and a one year high of $30.52. The company has a 50 day moving average price of $21.19 and a 200 day moving average price of $23.82.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on VCYT shares. The Goldman Sachs Group dropped their price objective on Veracyte from $32.00 to $28.00 and set a “buy” rating for the company in a report on Monday, April 15th. Needham & Company LLC raised their price objective on Veracyte from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. William Blair reiterated an “outperform” rating on shares of Veracyte in a report on Friday, February 23rd. Finally, Morgan Stanley dropped their target price on shares of Veracyte from $22.00 to $21.00 and set an “underweight” rating for the company in a research report on Monday, February 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

Insider Activity

In related news, Director Karin Eastham sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $21.65, for a total transaction of $216,500.00. Following the transaction, the director now directly owns 33,125 shares of the company’s stock, valued at approximately $717,156.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.60% of the company’s stock.

About Veracyte

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.